#Paris #France #Rare Diseases #Norgine #Theravia

Norgine Expands Its Rare Disease Portfolio Through Acquisition of Theravia

In a strategic move aimed at fortifying its commitment to rare diseases, Norgine has announced the acquisition of Theravia, an international pharmaceutical company known for its specialized treatments for patients suffering from rare and debilitating conditions. This acquisition marks a significant milestone in Norgine's pursuit of sustainable growth and amplifies its position as a premier partner for commercializing rare and specialty pharmaceuticals across Europe.

Norgine's acquisition of Theravia comes shortly after other notable collaborations and acquisitions, including its recent deals with Fennec Pharma for PEDMARQSI® and X4 Pharma for mavorixafor. The company's ongoing focus on expanding its footprint in the rare diseases therapeutic area reflects its dedication to addressing high unmet medical needs.

Theravia has established itself as a leader in developing innovative solutions, successfully launching life-saving therapies that significantly improve patient outcomes. Their product lineup includes SIKLOS®, a treatment for sickle cell disease, as well as ORPHACOL®, intended for those with a genetic disorder affecting bile production. Both products fit seamlessly into Norgine’s existing portfolio, enhancing its capabilities in the rare hematology and hepatology sectors.

Norgine’s CEO, Janneke van der Kamp, expressed enthusiasm about the acquisition, stating, “This is a unique opportunity for Norgine to bolster our growth trajectory and rare disease portfolio. We have a strong legacy of delivering innovative treatments to patients and we are prepared to help Theravia's products reach their full potential.”

In a joint statement, Franck Hamalian, CEO of Theravia, highlighted the merger's expansive potential: “Uniting our companies combines our expertise and geographical reach to establish a European champion in the realm of rare and ultra-rare diseases. This collaboration will facilitate broader access to essential medicines for patients with high unmet needs.”

With this acquisition, Norgine enhances its rare disease portfolio, now comprising six core products: PEDMARQSI®, eflornithine, mavorixafor, AGILUS®, SIKLOS®, and ORPHACOL®. This expanded repertoire will not only contribute to Norgine’s growth but also solidify its stance as a key player in the rare disease domain, offering critical therapies that can drive substantial advancements in patient care in the coming years.

The acquisition is pending customary regulatory approvals, but Norgine is eager to advance its platform for future growth, including potential acquisitions and in-licensing opportunities that align with its strategic vision. The attention to nurturing this space emphasizes Norgine's mission to be at the forefront of pharmaceutical innovation, particularly in areas where patient needs are most pressing.

About Theravia

Theravia is an international pharmaceutical company dedicated to tackling rare and neglected diseases. Formed through the merger of Addmedica and CTRS, it focuses on addressing the unmet needs of patients with challenging conditions.

Notable Products from Theravia

• - SIKLOS®: A medication that aids individuals with sickle-cell syndrome in preventing painful, recurrent crises that can occur when abnormal red blood cells obstruct blood flow to organs. It is available in 17 countries.
• - ORPHACOL®: This bile acid supplement treats newborns, children, and adults who cannot produce bile due to genetic disorders. The medication is marketed in 23 countries and is essential for preventing liver damage that could lead to severe complications.

Future Prospects

As Norgine moves forward, the integration of Theravia’s innovations is expected to bolster its standing in the pharmaceuticals industry while delivering vital treatments to those in need. With a rich background in pharmaceutical development and commercialization leadership, Norgine is set to lead the charge in providing exceptional healthcare solutions to an underserved market, benefiting countless patients throughout Europe and beyond.